

In the Claims:

Cancel claims 1-34.

Add the following new claims:

~~35~~ ~~34~~. (New) A method of screening for candidate compounds capable of modulating the activity of a G-protein coupled receptor polypeptide, comprising:

- B4
- (a) contacting a test compound with a cell or tissue comprising an expression vector capable of expressing a polypeptide comprising an amino acid sequence as set forth in SEQ ID NO:2, or encoded by ATCC deposit PTA-2682, under conditions in which said polypeptide is expressed; and
- (b) selecting as candidate modulating compounds those test compounds that modulate activity of the G-protein coupled receptor polypeptide,

wherein said candidate modulating compounds are useful for the treatment of a lung disorder.

~~36~~ ~~35~~. (New) The method according to claim 34 wherein said cells are CHO cells.

~~37~~ ~~36~~. (New) The method according to claim 34 wherein said cells comprise a vector comprising the coding sequence of the beta lactamase gene under the control of NFAT response elements.

~~38~~ ~~37~~. (New) The method according to claim 36 wherein said cells further comprise a vector comprising the coding sequence of G alpha 15 under conditions wherein G alpha 15 is expressed.

~~39~~ ~~38~~. (New) The method according to claim 36 wherein said cells comprise a vector comprising the coding sequence of the beta lactamase gene under the control of CRE response elements.

~~40~~ ~~39~~. (New) The method according to claim 34 wherein said cells are HEK cells.

~~41~~ ~~40~~. (New) The method according to claim 34 wherein said cells comprise a vector comprising the coding sequence of the beta lactamase gene under the control of CRE response elements.

~~42~~ ~~41~~. (New) The method according to claim 37 wherein said cells express the polypeptide at intermediate levels.

~~43~~ ~~42~~. (New) The method according to claim 37 wherein said cells express the polypeptide at high levels.

~~44~~ ~~43~~. (New) The method according to claim 38 wherein said cells express the polypeptide at intermediate levels.

45 ~~44~~. (New)
at high levels.

The method according to claim 38 wherein said cells express the polypeptide

46 ~~45~~. (New)
small molecule.

The method according to claim 37 wherein said candidate compound is a

47 ~~46~~. (New)
peptide.

The method according to claim 37 wherein said candidate compound is a

48 ~~47~~. (New)
antisense molecule.

The method according to claim 37 wherein said candidate compound is an

49 ~~48~~. (New)
small molecule.

The method according to claim 38 wherein said candidate compound is a

50 ~~49~~. (New)
peptide.

The method according to claim 38 wherein said candidate compound is a

51 ~~50~~. (New)
antisense molecule.

The method according to claim 38 wherein said candidate compound is an

52 ~~51~~. (New)
agonist.

The method according to claim 37 wherein said candidate compound is an

53 ~~52~~. (New)
antagonist.

The method according to claim 37 wherein said candidate compound is an

54 ~~53~~. (New)
agonist.

The method according to claim 38 wherein said candidate compound is an

55 ~~54~~. (New)
antagonist.

The method according to claim 38 wherein said candidate compound is an

56 ~~55~~. (New) The method according to claim 34 wherein said candidate compound is
useful for treating pulmonary disorders selected from the group consisting of: lung cancer;
bronchopulmonary dysplasia; Pancoast tumors; and post-inflammatory pseudotumor.

57 ~~56~~. (New)
at low levels.

The method according to claim 37 wherein said cells express beta lactamase

58 ~~57~~. (New)
at high levels.

The method according to claim 37 wherein said cells express beta lactamase

59 ~~58~~. (New)
at low levels.

The method according to claim 38 wherein said cells express beta lactamase

60 ~~59~~. (New)
at high levels.

The method according to claim 38 wherein said cells express beta lactamase